Ventyx Biosciences: The combination of Vtx3232 with GLP-1 receptor agonist Semaglutide showed an increase in efficacy on the primary endpoint compared to using Semaglutide/Vtx3232 alone.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.